Trial Profile
An Investigator-sponsored, Phase 1/2 Trial of the Oral XPO1 Inhibitor Selinexor (KPT-330) Monotherapy and in Combination With Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 15 Nov 2022 Planned End Date changed from 1 May 2024 to 1 Nov 2024.
- 15 Nov 2022 Status changed from recruiting to active, no longer recruiting.